Michael Flannery: Life Goes On: My Journey with Cholangiocarcinoma
Michael’s Journey: Overcoming Cholangiocarcinoma with Resilience, creative persistence, Hope, and Action gave him back a normal life
Steve Holmes Patient Survivor: 14000 kilometre Cycling Circumnavigation of Australia
Cycling to Empower patients. Transform survival outcomes. Support our innovative cancer response strategies and make a real difference today.
The Checkpoint Pathway: Ipilimumab and Keytruda immunotherapy combination
Discover how the combination of Ipilimumab and Keytruda removes the brakes and disguises cancer cells use to evade the immune system, offering new hope through immunotherapy.
Understanding BRCA1 and BRCA2 in Cholangiocarcinoma
Discover how BRCA1, BRCA2, and BAP1 genes influence cholangiocarcinoma and why understanding them is crucial for effective treatment.
Exploring the TAS-120-205 Trial: Understanding FGFR2 Inhibitor Impact on Cholangiocarcinoma Treatment”
Discover the TAS-120-205 trial's insights into FGFR2 inhibitors and their role in cholangiocarcinoma treatment.
Bile Gone Bad-Article 3: Understanding Bile Duct Damage and Bile Duct Cancers
Uncover the hidden link between poor bile composition and the alarming rise in bile duct cancer rates.
Michael Flannery: Life Goes On: My Journey with Cholangiocarcinoma
Michael’s Journey: Overcoming Cholangiocarcinoma with Resilience, creative persistence, Hope, and Action gave him back a normal life
Steve Holmes Patient Survivor: 14000 kilometre Cycling Circumnavigation of Australia
Cycling to Empower patients. Transform survival outcomes. Support our innovative cancer response strategies and make a real difference today.
The Checkpoint Pathway: Ipilimumab and Keytruda immunotherapy combination
Discover how the combination of Ipilimumab and Keytruda removes the brakes and disguises cancer cells use to evade the immune system, offering new hope through immunotherapy.
Understanding BRCA1 and BRCA2 in Cholangiocarcinoma
Discover how BRCA1, BRCA2, and BAP1 genes influence cholangiocarcinoma and why understanding them is crucial for effective treatment.
Exploring the TAS-120-205 Trial: Understanding FGFR2 Inhibitor Impact on Cholangiocarcinoma Treatment”
Discover the TAS-120-205 trial's insights into FGFR2 inhibitors and their role in cholangiocarcinoma treatment.
Bile Gone Bad-Article 3: Understanding Bile Duct Damage and Bile Duct Cancers
Uncover the hidden link between poor bile composition and the alarming rise in bile duct cancer rates.
